Document is current
Any future updates will be listed below
-
Authors
Gatson, Na Tosha N. https://orcid.org/0000-0003-1881-3520
Bross, Shane P.
Odia, Yazmin https://orcid.org/0000-0003-3602-3899
Mongelluzzo, Gino J. https://orcid.org/0000-0002-8324-0872
Hu, Yirui https://orcid.org/0000-0002-0477-0155
Lockard, Laura
Manikowski, Jesse J.
Mahadevan, Anand https://orcid.org/0000-0003-3555-4217
Kazmi, Syed A. J. https://orcid.org/0000-0002-1577-8419
Lacroix, Michel https://orcid.org/0000-0003-3198-6979
Conger, Andrew R. https://orcid.org/0000-0002-3561-4403
Vadakara, Joseph https://orcid.org/0000-0002-5796-0737
Nayak, Lakshmi
Chi, T. Linda https://orcid.org/0000-0001-7352-4890
Mehta, Minesh P. https://orcid.org/0000-0002-4812-5713
Puduvalli, Vinay K. https://orcid.org/0000-0001-8396-9500
-
Funding
Funding for this research was provided by:
Geisinger Health System Foundation (01100000000000, Account #341020–752025)
- License Information
-
More Information
Article History
Received: 13 May 2020
Accepted: 17 June 2020
First Online: 29 June 2020
Compliance with ethical standards
:
: <i>M. Mehta</i>: Consulting for Karyopharm, Tocagen, Astra-Zeneca, Blue Earth Diagnostics, Celgene, Abbvie. Board of Directors: Oncoceutics. <i>N. Gatson</i>: Advisory Board for Novocure. <i>Y. Odia</i>: Advisory Board for Novocure and Abbvie and Trial Support: Novocure and BMS. All remaining authors declare that they have no conflicts of interest.
: As a retrospective study all treatments were part of routine care and thereby ethical approval was waived by the Geisinger Health Ethics Committee.
